Clinical Trial Update: An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

An open-label, long-term Phase 3 study evaluating oral treprostinil in subjects with pulmonary arterial hypertension has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Treprostinil (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2022-06-02